Market Research Reports

Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts 2010 - 2017

78pages
Published Date: 2012-06-18
 

Description


This report analyzes the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) for the period 2010 to 2017. The major product segments in this market consist of bronchodilators, anti-inflammatories, and combination therapies. The report also describes the key influencing factors for the global asthma and COPD market. Market analysis and forecasts are provided for the period 2010 through 2017.

Definition, estimates & forecast of the global asthma and COPD market from 2010 to 2017
  • Analysis of sub-segments for asthma and COPD market
  • Analysis of the latest trends in the industry 
  • Acumen into the size and shape of the market growth

This research is specially designed to estimate and analyze the demand and performance of the global asthma and COPD market. The report covers all the major segments of asthma and COPD market and provides in-depth analysis, market revenue, and trend analysis by segments and statistically refined forecast for the segments covered. The in-depth research and high level analysis will allow asthma and COPD product manufacturers, service providers, marketing companies, research and development agencies to make informed decisions about asthma and COPD manufacturing, marketing, growth strategies and how best to gain competitive advantage.

The report presents detailed analysis and forecast for the global and China asthma and COPD market based on the following segmentation:

Product Types
Bronchodilators
  •         Short Acting Bronchodilators
  •         Long Acting Bronchodilators
  •         Anticholinergics
Anti-Inflammatories
  •         Inhaled Corticosteroids 
  •         Anti-Leukotriene 
  •         Monoclonal Antibodies
Combination Therapies

Table of Contents


CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
1.3 METHODOLOGY

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 ASTHMA AND COPD MARKET
3.1 MARKET OVERVIEW
3.2 INCREASING ASTHMA AND COPD PREVALENCE AND TRENDS
      3.2.1 Region wise estimate of asthma patients, 2007-2011(Million) 
      3.2.1 Region wise Estimate of COPD patients, 2007-2011 (Million) 
3.3 PRODUCT TREND ANALYSIS
3.4 ASTHMA DISEASE OVERVIEW
      3.4.1 ASTHMA PATIENT FORECASTS BY GEOGRAPHY, 2012 - 2017 (MILLION) 
      3.4.2 PATIENTS SUFFERING FROM ASTHMA, CHINA, 2012 - 2017 (MILLION) 
3.5 COPD DISEASE OVERVIEW
3.6 PATIENT FORECASTS – COPD PATIENTS BY GEOGRAPHY,  2012 – 2017 (MILLION) 
      3.6.1 PATIENTS SUFFERING FROM COPD, CHINA, 2010 - 2017 (MILLION) 
3.7 GROWTH DRIVERS
      3.7.1 INCREASE IN POPULATION SUSCEPTIBLE TO INDOOR AIR POLLUTANTS
      3.7.2 DAILY EXPOSURE TO HAZARDOUS WORKING ENVIRONMENT LEADS TO GROWTH OF ASTHMA AND COPD
      3.7.3 GROWING AGING POPULATION
      3.7.4 INCREASING POPULATION OF SMOKERS WILL SUPPORT THE GROWTH OF ASTHMA AND COPD MARKET
      3.7.5 INFLUX OF POLLUTANTS IN THE AIR
      3.7.6 INCREASE IN DISPOSABLE INCOME AND HEALTHCARE FACILITY
3.8 MARKET RESTRAINTS
      3.8.1 PATENT EXPIRY OF MANY BLOCKBUSTER BRANDS WILL CREATE PRESSURE
      3.8.2 OVERALL HIGH COST OF ASTHMA TREATMENT IS A CHALLENGE FOR PATIENTS
              3.8.2.1 Uninsured people - a challenge
      3.8.3 LONG TREATMENT CONTINUATION
3.9 PORTER FIVE FORCES MODEL
      3.9.1 BARGAINING POWER OF SUPPLIER
      3.9.2 BARGAINING POWER OF BUYER
      3.9.3 RIVALRY AMONG EXISTING COMPETITORS
      3.9.4 THREAT OF NEW ENTRANTS
      3.9.5 THREAT OF SUBSTITUTE PRODUCTS OR SERVICES

CHAPTER 4 ASTHMA AND COPD MARKET BY PRODUCT TYPE
4.1 ASTHMA AND COPD DRUG REVENUE FORECASTS
4.2 BRONCHODILATORS
      4.2.1 REVENUE FORECASTS FOR BRONCHODILATORS
      4.2.2 SHORT ACTING BRONCHODILATORS
                4.2.2.1 Revenue Forecasts for Short-Acting Bronchodilators
      4.2.3 LONG-ACTING BRONCHODILATORS
                4.2.3.1 Revenue Forecasts for Long-Acting Bronchodilators
      4.2.4 ANTICHOLINERGICS BRONCHODILATORS
                4.2.4.1 Revenue Forecasts Anticholinergics
4.3 ANTI-INFLAMMATORIES
                4.3.1.1 Revenue Forecasts for Anti-Inflammatories
      4.3.2 INHALED CORTICOSTEROIDS
                4.3.2.1 Revenue Forecasts for Inhaled Corticosteroids
      4.3.3 ANTI-LEUKOTRIENES
                4.3.3.1 Revenue Forecasts for Anti-Leukotrienes
      4.3.4 MONOCLONAL ANTIBODIES
                4.3.4.1 Revenue Forecasts for Monoclonal Antibodies
4.4 COMBINATION THERAPIES
      4.4.1 REVENUE FORECASTS FOR COMBINATION THERAPIES

CHAPTER 5 ASTHMA DRUG MARKET ANALYSIS
5.1 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION) 
5.2 ASTHMA PATHOPHYSIOLOGY
5.3 ASTHMA DRUG REVENUE BY BRNAD, 2009 - 2011 (USD MILLION) 
      5.3.1 MEDICATION
               5.3.1.1 Short-Acting Beta2-Agonists
               5.3.1.2 Inhaled Corticosteroids
               5.3.1.3 Long-Acting Bronchodilators
               5.3.1.4 Leukotriene Modifiers
               5.3.1.5 Mast Cell Stabilizers
               5.3.1.6 Methyxanthines
               5.3.1.7 Monoclonal Antibodies
               5.3.1.8 Oral Corticosteroids
5.4 ADHERENCE
      5.4.1 MEDICATION ADHERENCE BY AGE GROUP, 2011
5.5 ASTHMA - COST TRENDS
5.6 EMERGING TREATMENT OPTIONS FOR ASTHMA

CHAPTER 6 COPD MARKET ANALYSIS
6.1 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION) 
6.2 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION) 
6.3 EXISTING MEDICATION FOR COPD
6.4 COPD DRUG MARKET SHARE 2011 VS 2017
      6.4.1 BRONCHODILATORS
      6.4.2 LONG-ACTING ANTICHOLINERGICS
      6.4.3 LONG-ACTING Β2-AGONISTS
      6.4.4 SHORT-ACTING BRONCHODILATORS
6.5 INHALED CORTICOSTEROIDS
6.6 COMBINATION THERAPIES
      6.6.1 Β2-AGONISTS AND ANTICHOLINERGICS
      6.6.2 LABAS AND INHALED CORTICOSTEROIDS
6.7 EMERGING TRENDS IN COPD THERAPY

CHAPTER 7 DRUG BRAND DYNAMICS
7.1 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
7.2 SYMBICORT REVENUE (USD MILLION), 2009 – 2014
7.3 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
7.4 SINGULAIR REVENUE (USD MILLION), 2009 - 2014

CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 COMPETITIVE STRATEGY BY KEY PLAYERS
8.2 MARKET SHARE BY KEY PLAYERS, 2011
8.3 KEY ASTHMA & COPD DRUGS BY REVENUE, 2009 – 2011 (USD MILLION)
 
CHAPTER 9 COMPANY PROFILE
9.1 NOVARTIS AG
       9.1.1 COMPANY OVERVIEW
       9.1.2 FINANCIAL OVERVIEW: 
       9.1.3 RESPIRATORY DIVISION NET SALES
       9.1.4 SEGMENT OVERVIEW
       9.1.5 GEOGRAPHICAL OVERVIEW
       9.1.6 RECENT DEVELOPMENT
9.2 MERCK & CO. 
       9.2.1 COMPANY OVERVIEW
       9.2.2 FINANCIAL OVERVIEW: 
       9.2.3 GEOGRAPHICAL OVERVIEW
       9.2.4 RECENT DEVELOPMENT
9.3 GLAXOSMITHKLINE PLC
       9.3.1 COMPANY OVERVIEW
       9.3.2 FINANCIAL OVERVIEW: 
       9.3.3 SEGMENT OVERVIEW
       9.3.4 GEOGRAPHICAL OVERVIEW
       9.3.5 RECENT DEVELOPMENT
9.4 BOEHRINGER INGELHEIM GMBH (BOEHRINGER) 
       9.4.1 COMPANY OVERVIEW
       9.4.2 FINANCIAL OVERVIEW: 
       9.4.3 SEGMENT OVERVIEW
       9.4.4 GEOGRAPHICAL OVERVIEW
       9.4.5 RECENT DEVELOPMENT
9.5 NYCOMED
       9.5.1 COMPANY OVERVIEW
       9.5.2 FINANCIAL OVERVIEW: 
       9.5.3 GEOGRAPHICAL OVERVIEW
       9.5.4 RECENT DEVELOPMENT


LIST OF FIGURES

FIG. 1 REGION WISE ESTIMATE OF ASTHMA PATIENTS, 2007-2011 (MILLION)
FIG. 2 REGION WISE ESTIMATE OF COPD PATIENTS, 2007-2011 (MILLION)
FIG. 3 CHINESE ASTHMA PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 4 CHINESE COPD PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 5 AIR POLLUTION MARKET SHARE FROM DIFFERENT INDUSTRIES
FIG. 6 CHILDREN AGED (0-18) UNINSURED PERCENTAGE, 2003 - 2010
FIG. 7 ASTHMA AND COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 8 BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 9 SHORT-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 10 LONG-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 11 ANTICHOLINERGICS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 12 ANTI-INFLAMMATORIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 13 INHALED CORTICOSTEROIDS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 14 ANTI-LEUKOTRIENES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 15 MONOCLONAL ANTIBODIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 16 COMBINATION THERAPIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 17 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 18 ASTHMA DRUG REVENUE BY BRNAD, 2009- 2011 (USD MILLION)
FIG. 19 MEDICATION ADHERENCE BY AGE GROUP, 2011
FIG. 20 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 21 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)
FIG. 22 COPD DRUG MARKET SHARE 2011 VS 2017
FIG. 23 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
FIG. 24 SYMBICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 25 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
FIG. 26 SINGULAIR REVENUE (USD MILLION), 2009 - 2014
FIG. 27 PULMICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 28 MARKET SHARE BY KEY PLAYERS, 2011
FIG. 29 NOVARTIS AG, PERFORMANCE CHART (2007-2011)
FIG. 30 NOVARTIS AG, MARKET SHARE BY SEGMENT IN 2011
FIG. 31 NOVARTIS AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011)
FIG. 33 MERCK & CO. MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 34 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010)
FIG. 35 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2010
FIG. 36 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 37 BOEHRINGER INGELHEIM, MARKET SHARE BY SEGMENT IN 2011
FIG. 38 BOEHRINGER INGELHEIM, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 39 NYCOMED, MARKET SHARE BY GEOGRAPHY IN 2010

Market Overview



In the next five years, the global asthma and COPD drug market is expected to grow slowly, primarily because of expiry of patents of leading drug brands and price erosion in the market. However, by 2017, few novel drugs are expected to enter the asthma and COPD market, which will drive future growth. The existing asthma and COPD market is mainly driven by increasing patient population. The other factors that will drive the market include long term use of asthma and COPD drugs, increase in disposable income and improved access to medical care facilities in emerging economies. 

Competition in the asthma market is becoming intense due to the increased entry of combinational therapies, inhaled corticosteroids and beta-agonists. It is expected that Symbicort, Advair and Singulair would be the leading drugs of the global asthma and COPD market, while GlaxoSmithKline, AstraZeneca and Merck will continue to be the market leaders till the patents on their drugs expire in the coming years. 
The restraints in the asthma and COPD drug market is the threat of generic products in the market since many patents are going to expire in the coming years and governments have restrictions on healthcare budgets. The patent expiry of Merck’s Singulair in 2012 and Advairs’ in 2016 will shift the manufacturers to generic drugs. The purchasers will have high bargaining power due to large competition in the market and cost consciousness is expected to remain one of the major constraints in the COPD and asthma drug market.

The opportunities in the asthma and COPD market is huge as many companies are focusing on contract manufacturing outsourcing (CMO) and large players have entered this market with new product development. Increase in awareness about the benefits of timely diagnosis for asthma and COPD and availability of healthcare equipment for the detection of asthma and COPD in rural areas will further boost the market and growth opportunities for market players. 

In China, growth in urbanization and change in lifestyle has projected sharp increase in occurrence of asthma in the recent years. The occurrence of asthma symptoms is higher in urban areas as compared to rural areas. Air pollution and smoking are the most important factors which have led to the rapid increase in asthma and COPD patients in China.


Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases that cause chest symptoms leading to coughing, difficulty in breathing and wheezing. Asthma impacts a patient during the night time whereas COPD affect during the day time. They can coexist in the same individual whereas the cause and treatment of both these symptoms are different. Asthma is caused majorly due to allergies whereas COPD is a result of smoking. Asthma leads to inflammation of lungs and COPD leads to destructive illness of lungs. 

The report contains the global scenario of Asthma and COPD market discussing detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data and forecasts the Asthma and COPD market size, production forecasts along with key factors driving and restraining the market

This research is specially designed to estimate and analyze the demand, performance and size of “Asthma and COPD” Market in China and Global scenario. The research will provide in-depth analysis of value chain, product sales, trend analysis and demand by geography. The study will present a comprehensive assessment of the stakeholders’ strategies and winning imperatives for them.

Our report gives you the following advantages:

  • Find revenue predictions to 2017 for the World and China Asthma and COPD market
  • Discover revenue forecasts to 2017 for leading products, assessing market potentials
  • Assess leading companies, and discover their revenue prospects in near future
  • See revenue forecasts to 2017 for leading markets - US, Europe, Asia and China
  • Review R&D for asthma and COPD, assessing potential
  • Investigate competition and opportunities influencing the industry and market
  • Growth drivers and restrain of the industry and market from 2012 onwards

Enquiry Before Buying


Free Market Analysis


In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012. It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair, with most of those declines coming in the first full year following patent expiration. Also, the patent that provides market exclusivity for Singulair will expire in a number of major European markets in February 2013 and sales of Singulair in those markets will decline significantly thereafter. The patent that provides market exclusivity for Singulair in Japan will expire in 2016.

Asia Pacific region commanded for the largest share of global Asthma patients in 2010. The North America region will have the fastest growth rate for asthma patients at a CAGR of 3.9% in the world during 2010 - 2017. Globally, patients numbers are increasing continuously primarily due to cigarette smoking, continual exposure to hazardous particles or gases, increase in urbanization, change in lifestyle, and genetic factors. The growing number of asthmatics people from china and other economies will drive the revenue growth for the Asthma and COPD drugs market.

At present, long-acting beta2 agonist (LABA) / inhaled corticosteroid (ICS) combinations are the preferred combinations in the U.S. for treatment of asthma and/or COPD that include Advair (GlaxoSmithKline), Symbicort (AstraZeneca), and Dulera (Merck). LABA/ICS combinations are the most prescribed drugs because they offer efficacy and the convenience of delivering two drugs in one inhaler. The U.S. sales for asthma and COPD drugs are expected to total more than USDxxxx billion in 2012. 

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.

For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer).  Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).

Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.


Asthma is characterized by recurrent attacks of coughing, chest-tightening, breathlessness and wheezing as the airways narrow and swell that vary in severity and frequency. This chronic disease is most common among children.

factors-triggering-asthma

global-asthama-copd-market-size-and-forecast-market-2010-2017

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research